Biomarkers of Liver Injury in Non-Alcoholic Fatty Liver Disease
Diagnostic and Prognostic Significance
Keywords:
Non-Alcoholic Fatty Liver Disease, biomarkers, sickness progression, lifestyle intervention, predictive modeling, miR-122, FGF21, GDF15, ALT, adiponectin
Abstract
The prevalent liver condition known as Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by an abnormal buildup of fat in the liver cells. Conventional diagnostic methods are intrusive and impractical for routine screening, such as liver biopsies. The diagnostic and prognostic relevance of several biomarkers in NAFLD is examined in this study. A five-year observation period was used to track a longitudinal cohort of 500 NAFLD patients, with particular attention paid to biomarkers such as ALT, AST, CK-18, adiponectin, TNF-a, miR-122, FGF21, and GDF15. With miR-122, FGF21, and GDF15 demonstrating excellent predictive accuracy, the data showed substantial relationships between biomarker levels and disease development. Furthermore, adiponectin and ALT levels were markedly raised by lifestyle modifications. The aforementioned results bolster the efficacy of non-invasive biomarker-based diagnostics and underscore the significance of customized, non-pharmacological approaches in the handling of non-alcoholic fatty liver disease (NAFLD).
References
T. Biciusca, S. I. Stan, M. A. Balteanu, R. Cioboata, A. E. Ghenea, S. Danoiu, A. M. Bumbea, and V. Biciusca, "The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Sys-tematic Review," Diagnostics, vol. 13, no. 21, 2023, doi: 10.3390/diagnostics13213316.
E. Garrafa, A. Segala, M. Vezzoli, E. Bottani, B. Zanini, A. Vetturi, R. Bracale, C. Ricci, and A. Valerio, "Mi-tochondrial Dysfunction in Peripheral Blood Mononuclear Cells as Novel Diagnostic Tools for Non-Alcoholic Fatty Liver Disease: Visualizing Relationships with Known and Potential Disease Bi-omarkers," Diagnostics, vol. 13, no. 14, 2023, doi: 10.3390/diagnostics13142363.
S. Leonetti, R. I. Herzog, S. Caprio, N. Santoro, and D. Tricò, "Glutamate–serine–glycine index: A novel potential biomarker in pediatric non-alcoholic fatty liver disease," Children, vol. 7, no. 12, 2020, doi: 10.3390/children7120270.
C. V. Chandra Kumar, R. Skantha, and W. K. Chan, "Non-invasive assessment of metabolic dysfunction–associated fatty liver disease," Therapeutic Advances in Endocrinology and Metabolism, vol. 13, 2022, doi: 10.1177/20420188221139614.
R. Toita and J. H. Kang, "Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease," Toxicology Letters, vol. 332, 2020, doi: 10.1016/j.toxlet.2020.06.020.
L. A. Newman, M. J. Sorich, and A. Rowland, "Role of extracellular vesicles in the pathophysiology, diag-nosis and tracking of non-alcoholic fatty liver disease," Journal of Clinical Medicine, vol. 9, no. 7, 2020, doi: 10.3390/jcm9072032.
A. S. Bockarie, Y. A. Nartey, P. Nsiah, E. K. M. Edzie, D. Tuoyire, S. Acquah, S. Eliason, and B. Nkum, "Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients," Endocrinology, Diabetes and Metabolism, vol. 6, no. 6, 2023, doi: 10.1002/edm2.456.
T. C. F. Yip, F. Lyu, H. Lin, G. Li, P. C. Yuen, V. W. S. Wong, and G. L. H. Wong, "Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future," Clinical and Molecular Hepatology, vol. 29, 2023, doi: 10.3350/cmh.2022.0426.
P. Zeng, X. Cai, X. Yu, L. Huang, and X. Chen, "HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population," Journal of International Medical Research, vol. 51, no. 10, 2023, doi: 10.1177/03000605231204462.
R. A. El-Aziz, A. R. L. R. Alnaggar, M. I. M. Nabih, S. M. Ali, H. Khattab, and S. A. EL-Atty, "Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study," Clinical and Experimental Hepatology, vol. 6, no. 1, 2020, doi: 10.5114/CEH.2020.93053.
H. D. Nguyen and M. S. Kim, "Effects of chemical mixtures on liver function biomarkers in the Korean adult population: thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved," Envi-ronmental Science and Pollution Research, vol. 29, no. 52, 2022, doi: 10.1007/s11356-022-21090-4.
A. Eguchi, M. Iwasa, and H. Nakagawa, "Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets," Liver International, vol. 43, no. 2, 2023, doi: 10.1111/liv.15490.
F. Khaznadar, A. Petrovic, O. Khaznadar, H. Roguljic, K. Bojanic, L. Kuna Roguljic, S. Siber, R. Smolic, I. Bilic-Curcic, G. Y. Wu, and M. Smolic, "Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Pa-tients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy," Journal of Clinical Medicine, vol. 12, no. 20, 2023, doi: 10.3390/jcm12206561.
S. Ajaz, M. J. McPhail, L. Gnudi, F. M. Trovato, S. Mujib, S. Napoli, I. Carey, and K. Agarwal, "Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)," Mito-chondrion, vol. 57, 2021, doi: 10.1016/j.mito.2020.12.010.
A. M. Elghandour, E. A. Awad, R. H. A. Abdel-Hamid, and A. M. F. Mansour, "Evaluation of the role of hyaluronic acid as a potential biomarker for diagnosis of non-alcoholic fatty liver disease," Egyptian Journal of Hospital Medicine, vol. 83, no. 1, 2021, doi: 10.21608/EJHM.2021.158087.
P. Alajos and G. Gabriella, "Alcoholic liver disease – 2023," Orvosi Hetilap, vol. 164, no. 47, 2023, doi: 10.1556/650.2023.32921.
R. Al-Qarni, M. Iqbal, M. Al-Otaibi, M. Al-Saif, A. A. Alfadda, H. Alkhalidi, F. Bamehriz, and M. Hassanain, "Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease," Medicine (United States), vol. 99, no. 36, 2020, doi: 10.1097/MD.0000000000021463.
L. S. Pacheco, R. D. Bradley, C. A. M. Anderson, and M. A. Allison, "Changes in Biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) upon Access to Avocados in Hispanic/Latino Adults: Secondary Data Anal-ysis of a Cluster Randomized Controlled Trial," Nutrients, vol. 14, no. 13, 2022, doi: 10.3390/nu14132744.
K. Johnson, P. J. Leary, O. Govaere, M. J. Barter, S. H. Charlton, S. J. Cockell, D. Tiniakos, M. Zatorska, P. Bedossa, M. J. Brosnan, J. F. Cobbold, M. Ekstedt, G. P. Aithal, K. Clément, J. M. Schattenberg, J. Boursier, V. Ratziu, E. Bugianesi, Q. M. Anstee, and A. K. Daly, "Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance," JHEP Reports, vol. 4, no. 2, 2022, doi: 10.1016/j.jhepr.2021.100409.
K. E. Corey, R. Pitts, M. Lai, J. Loureiro, R. Masia, S. A. Osganian, J. L. Gustafson, M. M. Hutter, D. W. Gee, O. R. Meireles, E. R. Witkowski, S. M. Richards, J. H. Lacy, and K. A. Krajewski, "Correlating histopathological features of non-alcoholic fatty liver disease patients and advanced fibrosis," Nature Communications, vol. 13, no. 1, 2022, doi: 10.1038/s41467-022-30097-5.
V. Ponnusamy, S. Sinha, R. Sharma, A. R. Paul, S. Sekhar, A. Duseja, D. Dayal, A. Singhal, and R. Kochhar, "Role of Circulating MiRNAs in Early Detection of Non-Alcoholic Fatty Liver Disease in Obese Pediatric Population," Frontiers in Pediatrics, vol. 11, 2023, doi: 10.3389/FPED.2023.1188491.
R. K. Kelly, K. E. Kelly, R. Patel, D. K. Agrawal, and J. Y. Tsai, "Potential circulating biomarkers for the early detection of non-alcoholic fatty liver disease," Expert Review of Molecular Diagnostics, vol. 23, no. 1, 2023, doi: 10.1080/14737159.2023.2153578.
A. Baranova, L. Sidossis, and C. S. Mantzoros, "New imaging techniques and non-invasive biomarkers in NAFLD," Endocrine, vol. 78, no. 2, 2022, doi: 10.1007/S12020-022-03113-8.
L. L. Y. Chan, S. Y. Chong, W. L. Chong, A. L. L. Chua, J. C. H. Chan, and E. K. Tan, "Biochemical and his-tological assessment of non-alcoholic fatty liver disease in Singapore: a preliminary study," Singapore Med-ical Journal, vol. 61, no. 11, 2020, doi: 10.11622/smedj.2019129.
Y. Vali, J. Lee, J. Boursier, R. Spijker, Q. M. Anstee, P. M. M. Bossuyt, and W. M. Lijfering, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis," Journal of Hepatology, vol. 73, no. 2, 2020, doi: 10.1016/j.jhep.2020.03.036.
Y. Ando, H. Kuwano, Y. Saikawa, Y. I. Yamashita, and S. Eguchi, "Micrornas in non-alcoholic fatty liver disease: Recent advances and future perspectives," Frontiers in Medicine, vol. 8, 2021, doi: 10.3389/FMED.2021.637522.
E. K. A. Abo and E. E. Lotfy, "A Study of Hyaluronic Acid as A Predictive Biomarker in Non-alcoholic Fatty Liver Disease," Egyptian Journal of Health Care, vol. 14, no. 1, 2023, doi: 10.21608/EJHC.2022.276706.
L. Wang, Q. Meng, C. Wang, Y. Li, F. Su, X. Fan, Y. Liu, Z. Cheng, and Z. Liu, "Quantitative liver function tests and biomarker profiles for the evaluation of liver fibrosis and non-alcoholic fatty liver disease in patients with autoimmune hepatitis," Frontiers in Immunology, vol. 13, 2022, doi: 10.3389/fimmu.2022.1032957.
S. Bai, Q. Chen, R. Wang, J. Chen, X. Zhang, Y. Gu, Z. Zhao, Q. Zhang, H. Fan, H. Zhao, S. Chen, and H. Yuan, "New promising non-invasive biomarkers for diagnosing liver fibrosis in non-alcoholic fatty liver disease patients with normal and elevated ALT," Journal of Hepatology, vol. 77, 2022, doi: 10.1016/S0618-8278(22)00885-7.
Y. C. Yen, Y. J. Lai, C. H. Lin, Y. M. Chen, M. S. Lin, L. C. Hwang, and C. Y. Chen, "Predicting the development of non-alcoholic fatty liver disease in a large population: An empirical comparison of machine learning models," Healthcare, vol. 9, no. 9, 2021, doi: 10.3390/healthcare9091124.
R. E. Simmonds, J. Dunne, D. McNamara, C. F. Allen, C. Caussy, R. Loomba, R. Yu, and E. Brennan, "De-velopment of a direct biomarker of liver fibrosis using quantitative measurements of adiponectin cleaved isoforms in a well-characterised NAFLD cohort," Journal of Hepatology, vol. 75, no. 1, 2021, doi: 10.1016/S0618-8278(21)01067-8.
R. A. Harsono, A. F. A. Fattah, and W. Gunadi, "Serological biomarkers for early detection and monitoring of non-alcoholic fatty liver disease," Journal of Advances in Medicine and Medical Research, vol. 34, no. 23, 2022, doi: 10.9734/JAMMR/2022/V34I2331738.
J. Zhang, T. Huang, Y. Luo, J. Yang, X. Yan, B. Lin, Y. Lin, G. Shi, and J. Zhao, "Systemic Inflammatory Marker C-Reactive Protein and Risk of Non-Alcoholic Fatty Liver Disease in the Yongze Study," Journal of Clinical Medicine, vol. 9, no. 3, 2020, doi: 10.3390/jcm9030707.
M. Meroni, A. Alisi, and J. S. Bajaj, "Gut microbiome and non-alcoholic fatty liver disease: insights on mechanisms and therapy," Translational Research, vol. 227, 2021, doi: 10.1016/J.TRSL.2020.05.005.
A. Mansouri and Y. Wang, "The blood gut and liver axis in NAFLD: the role of gut microbiota-derived bile acids," Liver Research, vol. 5, no. 4, 2021, doi: 10.1016/J.LIVRES.2021.09.002.
E. Garrafa, A. Segala, M. Vezzoli, E. Bottani, B. Zanini, A. Vetturi, R. Bracale, C. Ricci, and A. Valerio, "Mi-tochondrial Dysfunction in Peripheral Blood Mononuclear Cells as Novel Diagnostic Tools for Non-Alcoholic Fatty Liver Disease: Visualizing Relationships with Known and Potential Disease Bi-omarkers," Diagnostics, vol. 13, no. 14, 2023, doi: 10.3390/diagnostics13142363.
S. Leonetti, R. I. Herzog, S. Caprio, N. Santoro, and D. Tricò, "Glutamate–serine–glycine index: A novel potential biomarker in pediatric non-alcoholic fatty liver disease," Children, vol. 7, no. 12, 2020, doi: 10.3390/children7120270.
C. V. Chandra Kumar, R. Skantha, and W. K. Chan, "Non-invasive assessment of metabolic dysfunction–associated fatty liver disease," Therapeutic Advances in Endocrinology and Metabolism, vol. 13, 2022, doi: 10.1177/20420188221139614.
R. Toita and J. H. Kang, "Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease," Toxicology Letters, vol. 332, 2020, doi: 10.1016/j.toxlet.2020.06.020.
L. A. Newman, M. J. Sorich, and A. Rowland, "Role of extracellular vesicles in the pathophysiology, diag-nosis and tracking of non-alcoholic fatty liver disease," Journal of Clinical Medicine, vol. 9, no. 7, 2020, doi: 10.3390/jcm9072032.
A. S. Bockarie, Y. A. Nartey, P. Nsiah, E. K. M. Edzie, D. Tuoyire, S. Acquah, S. Eliason, and B. Nkum, "Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients," Endocrinology, Diabetes and Metabolism, vol. 6, no. 6, 2023, doi: 10.1002/edm2.456.
T. C. F. Yip, F. Lyu, H. Lin, G. Li, P. C. Yuen, V. W. S. Wong, and G. L. H. Wong, "Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future," Clinical and Molecular Hepatology, vol. 29, 2023, doi: 10.3350/cmh.2022.0426.
P. Zeng, X. Cai, X. Yu, L. Huang, and X. Chen, "HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population," Journal of International Medical Research, vol. 51, no. 10, 2023, doi: 10.1177/03000605231204462.
R. A. El-Aziz, A. R. L. R. Alnaggar, M. I. M. Nabih, S. M. Ali, H. Khattab, and S. A. EL-Atty, "Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study," Clinical and Experimental Hepatology, vol. 6, no. 1, 2020, doi: 10.5114/CEH.2020.93053.
H. D. Nguyen and M. S. Kim, "Effects of chemical mixtures on liver function biomarkers in the Korean adult population: thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved," Envi-ronmental Science and Pollution Research, vol. 29, no. 52, 2022, doi: 10.1007/s11356-022-21090-4.
A. Eguchi, M. Iwasa, and H. Nakagawa, "Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets," Liver International, vol. 43, no. 2, 2023, doi: 10.1111/liv.15490.
F. Khaznadar, A. Petrovic, O. Khaznadar, H. Roguljic, K. Bojanic, L. Kuna Roguljic, S. Siber, R. Smolic, I. Bilic-Curcic, G. Y. Wu, and M. Smolic, "Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Pa-tients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy," Journal of Clinical Medicine, vol. 12, no. 20, 2023, doi: 10.3390/jcm12206561.
S. Ajaz, M. J. McPhail, L. Gnudi, F. M. Trovato, S. Mujib, S. Napoli, I. Carey, and K. Agarwal, "Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)," Mito-chondrion, vol. 57, 2021, doi: 10.1016/j.mito.2020.12.010.
A. M. Elghandour, E. A. Awad, R. H. A. Abdel-Hamid, and A. M. F. Mansour, "Evaluation of the role of hyaluronic acid as a potential biomarker for diagnosis of non-alcoholic fatty liver disease," Egyptian Journal of Hospital Medicine, vol. 83, no. 1, 2021, doi: 10.21608/EJHM.2021.158087.
P. Alajos and G. Gabriella, "Alcoholic liver disease – 2023," Orvosi Hetilap, vol. 164, no. 47, 2023, doi: 10.1556/650.2023.32921.
R. Al-Qarni, M. Iqbal, M. Al-Otaibi, M. Al-Saif, A. A. Alfadda, H. Alkhalidi, F. Bamehriz, and M. Hassanain, "Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease," Medicine (United States), vol. 99, no. 36, 2020, doi: 10.1097/MD.0000000000021463.
L. S. Pacheco, R. D. Bradley, C. A. M. Anderson, and M. A. Allison, "Changes in Biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) upon Access to Avocados in Hispanic/Latino Adults: Secondary Data Anal-ysis of a Cluster Randomized Controlled Trial," Nutrients, vol. 14, no. 13, 2022, doi: 10.3390/nu14132744.
K. Johnson, P. J. Leary, O. Govaere, M. J. Barter, S. H. Charlton, S. J. Cockell, D. Tiniakos, M. Zatorska, P. Bedossa, M. J. Brosnan, J. F. Cobbold, M. Ekstedt, G. P. Aithal, K. Clément, J. M. Schattenberg, J. Boursier, V. Ratziu, E. Bugianesi, Q. M. Anstee, and A. K. Daly, "Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance," JHEP Reports, vol. 4, no. 2, 2022, doi: 10.1016/j.jhepr.2021.100409.
K. E. Corey, R. Pitts, M. Lai, J. Loureiro, R. Masia, S. A. Osganian, J. L. Gustafson, M. M. Hutter, D. W. Gee, O. R. Meireles, E. R. Witkowski, S. M. Richards, J. H. Lacy, and K. A. Krajewski, "Correlating histopathological features of non-alcoholic fatty liver disease patients and advanced fibrosis," Nature Communications, vol. 13, no. 1, 2022, doi: 10.1038/s41467-022-30097-5.
V. Ponnusamy, S. Sinha, R. Sharma, A. R. Paul, S. Sekhar, A. Duseja, D. Dayal, A. Singhal, and R. Kochhar, "Role of Circulating MiRNAs in Early Detection of Non-Alcoholic Fatty Liver Disease in Obese Pediatric Population," Frontiers in Pediatrics, vol. 11, 2023, doi: 10.3389/FPED.2023.1188491.
R. K. Kelly, K. E. Kelly, R. Patel, D. K. Agrawal, and J. Y. Tsai, "Potential circulating biomarkers for the early detection of non-alcoholic fatty liver disease," Expert Review of Molecular Diagnostics, vol. 23, no. 1, 2023, doi: 10.1080/14737159.2023.2153578.
A. Baranova, L. Sidossis, and C. S. Mantzoros, "New imaging techniques and non-invasive biomarkers in NAFLD," Endocrine, vol. 78, no. 2, 2022, doi: 10.1007/S12020-022-03113-8.
L. L. Y. Chan, S. Y. Chong, W. L. Chong, A. L. L. Chua, J. C. H. Chan, and E. K. Tan, "Biochemical and his-tological assessment of non-alcoholic fatty liver disease in Singapore: a preliminary study," Singapore Med-ical Journal, vol. 61, no. 11, 2020, doi: 10.11622/smedj.2019129.
Y. Vali, J. Lee, J. Boursier, R. Spijker, Q. M. Anstee, P. M. M. Bossuyt, and W. M. Lijfering, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis," Journal of Hepatology, vol. 73, no. 2, 2020, doi: 10.1016/j.jhep.2020.03.036.
Y. Ando, H. Kuwano, Y. Saikawa, Y. I. Yamashita, and S. Eguchi, "Micrornas in non-alcoholic fatty liver disease: Recent advances and future perspectives," Frontiers in Medicine, vol. 8, 2021, doi: 10.3389/FMED.2021.637522.
E. K. A. Abo and E. E. Lotfy, "A Study of Hyaluronic Acid as A Predictive Biomarker in Non-alcoholic Fatty Liver Disease," Egyptian Journal of Health Care, vol. 14, no. 1, 2023, doi: 10.21608/EJHC.2022.276706.
L. Wang, Q. Meng, C. Wang, Y. Li, F. Su, X. Fan, Y. Liu, Z. Cheng, and Z. Liu, "Quantitative liver function tests and biomarker profiles for the evaluation of liver fibrosis and non-alcoholic fatty liver disease in patients with autoimmune hepatitis," Frontiers in Immunology, vol. 13, 2022, doi: 10.3389/fimmu.2022.1032957.
S. Bai, Q. Chen, R. Wang, J. Chen, X. Zhang, Y. Gu, Z. Zhao, Q. Zhang, H. Fan, H. Zhao, S. Chen, and H. Yuan, "New promising non-invasive biomarkers for diagnosing liver fibrosis in non-alcoholic fatty liver disease patients with normal and elevated ALT," Journal of Hepatology, vol. 77, 2022, doi: 10.1016/S0618-8278(22)00885-7.
Y. C. Yen, Y. J. Lai, C. H. Lin, Y. M. Chen, M. S. Lin, L. C. Hwang, and C. Y. Chen, "Predicting the development of non-alcoholic fatty liver disease in a large population: An empirical comparison of machine learning models," Healthcare, vol. 9, no. 9, 2021, doi: 10.3390/healthcare9091124.
R. E. Simmonds, J. Dunne, D. McNamara, C. F. Allen, C. Caussy, R. Loomba, R. Yu, and E. Brennan, "De-velopment of a direct biomarker of liver fibrosis using quantitative measurements of adiponectin cleaved isoforms in a well-characterised NAFLD cohort," Journal of Hepatology, vol. 75, no. 1, 2021, doi: 10.1016/S0618-8278(21)01067-8.
R. A. Harsono, A. F. A. Fattah, and W. Gunadi, "Serological biomarkers for early detection and monitoring of non-alcoholic fatty liver disease," Journal of Advances in Medicine and Medical Research, vol. 34, no. 23, 2022, doi: 10.9734/JAMMR/2022/V34I2331738.
J. Zhang, T. Huang, Y. Luo, J. Yang, X. Yan, B. Lin, Y. Lin, G. Shi, and J. Zhao, "Systemic Inflammatory Marker C-Reactive Protein and Risk of Non-Alcoholic Fatty Liver Disease in the Yongze Study," Journal of Clinical Medicine, vol. 9, no. 3, 2020, doi: 10.3390/jcm9030707.
M. Meroni, A. Alisi, and J. S. Bajaj, "Gut microbiome and non-alcoholic fatty liver disease: insights on mechanisms and therapy," Translational Research, vol. 227, 2021, doi: 10.1016/J.TRSL.2020.05.005.
A. Mansouri and Y. Wang, "The blood gut and liver axis in NAFLD: the role of gut microbiota-derived bile acids," Liver Research, vol. 5, no. 4, 2021, doi: 10.1016/J.LIVRES.2021.09.002.
Published
2024-06-18
How to Cite
Jabbar, N. A. M., & Bukhibkh, H. C. (2024). Biomarkers of Liver Injury in Non-Alcoholic Fatty Liver Disease. Central Asian Journal of Medical and Natural Science, 5(3), 576-588. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/2485
Section
Articles
Copyright (c) 2024 Nour Allah Mahdi Jabbar, Hawraa Chasib Bukhibkh
This work is licensed under a Creative Commons Attribution 4.0 International License.
